TVGN TEVOGEN BIO HOLDINGS INC

Tevogen Bio to Attend the 43rd Annual J.P. Morgan Healthcare Conference

Tevogen Bio to Attend the 43rd Annual J.P. Morgan Healthcare Conference

WARREN, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: ), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today announced that Founder and CEO Ryan Saadi, MD, MPH, will be attending the J.P. Morgan Healthcare Conference, January 13-16, 2025, in San Francisco, CA.

The J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together key stakeholders to discuss innovations and advancements in the sector.

For inquiries about Tevogen Bio’s JP Morgan events, please contact Communications at

About Tevogen Bio

Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence.

Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.

Contacts

Tevogen Bio Communications

T: 1 877 TEVOGEN, Ext 701



EN
10/12/2024

Underlying

TVGNTEVOGEN BIO HOLDINGS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TEVOGEN BIO HOLDINGS INC

 PRESS RELEASE
Free
TVGN TEVOGEN BIO HOL...

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a ...

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization WARREN, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with a distinguished global Contract Research Organization (“CRO”). If consummated, the proposed transaction could expand Tevogen’s clinical development capabilities and could support the Company’s evolution into a revenue-generating healthcare enterp...

17h / 7m 1 EN
 PRESS RELEASE
Free
TVGN TEVOGEN BIO HOL...

UPDATE - Tevogen Signs Letter of Intent to Evaluate Potential Acquisit...

UPDATE - Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus WARREN, N.J. and ROYAL OAK, Mich., Feb. 26, 2026 (GLOBE NEWSWIRE) --   (“Tevogen Bio Holdings Inc.”) (Nasdaq: ) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with (“Sciometrix”), a privately held healthcare technology and value-based care solutions provider headquartered in Michigan and developer of the Clinicus digital care management platform, that would, if ...

February 26, 2026 1 EN
 PRESS RELEASE
Free
TVGN TEVOGEN BIO HOL...

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sc...

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus WARREN, N.J. and ROYAL OAK, Mich., Feb. 26, 2026 (GLOBE NEWSWIRE) --   (“Tevogen Bio Holdings Inc.”) (Nasdaq: ) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with (“Sciometrix”), a privately held healthcare technology and value-based care solutions provider headquartered in Michigan and developer of the Clinicus digital care management platform, that would, if consummat...

February 26, 2026 1 EN
 PRESS RELEASE
Free
TVGN TEVOGEN BIO HOL...

Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to ...

Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders WARREN, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ) today announced that its Board of Directors has expressed its intention to evaluate the potential declaration of a one-time special cash dividend to shareholders, contingent upon the achievement of specified financial milestones to be determined at a future date, which could include revenue and earnings targets. Any consideration of a special dividend would be subject to the Company’s future financial per...

January 30, 2026 1 EN
 PRESS RELEASE
Free
TVGN TEVOGEN BIO HOL...

Tevogen to Align Long-Term Stock-Based Incentive Program With Company ...

Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue WARREN, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today announced that the current time- and individual performance-based long-term stock incentive program will be modified to align awards with defined company milestones including revenue. The updated program will be applicable to all employees, officers, directors and consultants who are eligible to participate in the Company’s long term incentives plan. Tevogen Founder and CEO, Dr. Ry...

January 29, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch